期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PAK5和MDRI／P-gP在卵巢癌细胞紫杉醇耐药中的表达和临床意义 被引量：3

在线阅读 下载PDF
导出
摘要 卵巢癌是最常见的妇科恶性肿瘤之一，其病死率居女性生殖系统肿瘤首位，由于大多数卵巢癌发病隐匿，且缺乏准确有效的早期诊断方法。目前手术联合化疗的综合治疗在一定程度上延长了晚期卵巢癌患者的生存时间；但多数患者在18～24个月后复发，其5年生存率〈30％。肿瘤细胞减灭术加以铂类和紫杉醇为基础的联合化疗已成为当前卵巢癌的标准治疗手段。
作者 邹竞慧 李笛悠 张萍
机构地区 上海交通大学医学院附属新华医院妇科
出处 《浙江临床医学》 2016年第2期375-377,共3页 Zhejiang Clinical Medical Journal
基金 上海市卫生局课题项目（20144Y0144）
关键词 卵巢癌细胞 紫杉醇 临床意义 P-GP 女性生殖系统肿瘤 肿瘤细胞减灭术 卵巢癌患者 耐药
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1傅云峰,谢幸,叶大风.卵巢癌细胞耐药机制及其对策研究进展[J].国外医学（妇产科学分册）,2005,32(4):229-232. 被引量：5
  • 2Penson RT,Oliva E,Skates SJ,et al.Expression ofmuhidrug resistance-1 protein inversely correlates with paclitaxel response and surviral in ovarian cancer patients:a study in serial samples.GyneeolOncol,2004, 93(1):98-106.
  • 3Koji Matsuo,MD,Michele L.Eno,MD Multi-drug resistance gene (MDR-1) arid risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol,2011,34(5):488-493.
  • 4H Chend Hao.Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression .British Journal of Cancer, 2009,101 (3): 432-440.
  • 5GiffordG,Paul J,VaseyPA,et al.The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients.Clin Cancer Res,2004,10(13):4420-4426.
  • 6Kennedy RD,QuinnJE,MuUan PB,et al.The role of BRCA1 in the cellular response to chemotherapy.J Nail Cancer Inst,2004,96(22):1659-1668.
  • 7Murray S,Briasoulis E,Linardou H,et al.Taxane resistance in breast cancer:Mechanisms,predictive biomarkers and circumvention strategies. Cancer treatment reviews,2012,38(7):890-903.
  • 8Kim R,,Emi M,Tanabe K,et al.Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.Cancer,2004,101(11):2491-2502.
  • 9Murray S,Briasoulis E,Linardou H,et al.Taxane resistance in breast cancer:Mechanisms,predictive biomarkers and circumvention strategies. Cancer treatment reviews,2012,38(7):890-903.
  • 10Vergara D,Tinelli A,Iannone A, et al.The impact ofproteomics in the understanding of the molecular basis of Paclitaxel-resistance in ovarian tumors.Current cancer drug targets,2012j2(8):987-997.

二级参考文献22

  • 1Da-QiangLi Zhi-BiaoWang JinBai JieZhao YuanWang KaiHu Yong-HongDu.Reversal of multidrug resistance in drug-resistant human gastric cancer cell line SGC7901/VCR by antiprogestin drug mifepristone[J].World Journal of Gastroenterology,2004,10(12):1722-1725. 被引量：29
  • 2Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol,2004,93(1):98-106.
  • 3Selvakumaran M, Pisarcik DA, Bao R, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res,2003,63(6): 1311-1316.
  • 4Gifford G, Paul J, Vasey PA, et al. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res,2004,10( 13):4420-4426.
  • 5Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst,2004,96(22):1659-1668.
  • 6Kim R, Emi M, Tanabe K, et al. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer,2004,101 (11):2491-2502.
  • 7Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem,2003,278(21): 19245-19256.
  • 8Tanyi JL, Haseg.awa Y, Lapushin R, et al. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res,2003,9(10 pt 1):3534-3545.
  • 9Sudo T, Nitta M, Saya H, et al. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res, 2004,64(7):2502-2508.
  • 10Gore ME, Atkinson R J, Thomas H, et al. A phase Ⅱ trim of ZD0473 in platinum pretreated ovarian cancer. Eur J Cancer,2002,38(18):2416-2420.

共引文献7

同被引文献19

引证文献3

二级引证文献2

浙江临床医学
2016年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部